The burgeoning market for noninvasive prenatal testing has to date been dominated by next-generation sequencing-based offerings, but that may change next year when CellScape launches its Clarity test.

And, according to its founder and executive chair, Karen Drexler, the firm believes its microarray-based offering will give it an advantage in the NIPT market, not only because it will at launch be able to test for the "top microdeletion syndromes" as well as other defects, but because of the market's familiarity with microarrays.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.